News

  1. Blinded Diagnostics Appoints Patricia H. Averette As VP, Business Development 1/3/2013

    Blinded Diagnostics announced the expansion of their business development efforts by appointing Patricia H. Averette, a seasoned health care professional with a solid background in Hematology Lab Diagnostics, as the new Vice President of Business Development. 

  2. Thomson Reuters Spotlights The Impact Of Personalized Medicine On Pharmaceutical R&D 12/14/2012

    The IP & Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced the publication of a new report that provides a comprehensive view of the potential effects of personalized medicine on drug research and development.

  3. PHT Corporation Patents 'Time Travel' For Clinical Research 12/11/2012

    It’s now possible for clinical trial researchers to control time, thanks to PHT Corporation’s patented Time Travel technology.PHT is the world’s leading provider of systems used to collect patient-driven eData for clinical research.

  4. Express Diagnostics Int'l, Inc. Appoints Blinded Diagnostics To Offer Drugs Of Abuse And Alcohol Testing For Use In Pharmaceutical Clinical Trials 12/6/2012

    Blinded Diagnostics recently announced the expansion of their diagnostic product portfolio with the addition of an extensive line of screening tests for drugs of abuse and alcohol from Express Diagnostics Int’l, Inc. (EDI) of Blue Earth, MN.

  5. Peregrine Pharmaceuticals Announces Significant Progress In Advancing Its Cotara Program Into A Pivotal Phase III Trial 12/5/2012

    Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it has made significant progress in advancing its Cotara program into late-stage development through its agreement with the U.S.

  6. Thomson Reuters Empowers Drug Development And Clinical Professionals To Develop Better, Faster Clinical Trials With Best-In-Class Intelligence Solution 12/5/2012

    The IP & Science business of Thomson Reuters, the world’s leading provider of intelligent information for businesses and professionals, recently announced  a preview of its newest intelligence solution, Thomson Reuters Cortellis for Clinical Trials Intelligence.

  7. A Collaboration For More Effective Centralized Cardiac Safety Services 12/3/2012

    Spaulding Clinical Research Announces Collaboration with Blinded Diagnostics for centralized cardiac safety services for select pharmaceutical clients.

  8. Spaulding Clinical Research Announces Collaboration With Blinded Diagnostics For Centralized Cardiac Safety Services For Select Pharmaceutical Clients 12/3/2012

    Spaulding Clinical Research has agreed to offer ECG services using the new Spaulding webECG Diagnostic ECG Management system for late stage clinical trials through Blinded Diagnostics.

  9. Immunovative Announces Regulatory Clearance To Conduct A Phase II/III Clinical Trial In Advanced Metastatic Breast Cancer For AlloStim™ 11/29/2012

    Immunovative, Inc. ("IMUN" or the "Company") (OTCQB: IMUN) announces today that Immunovative Therapies, Ltd. ("ITL") has been granted regulatory clearance from Thailand authorities to advance its lead AlloStim™ immunotherapy product candidate to the Phase II/III clinical development stage in advanced metastatic breast cancer.

  10. Phase 2b Data Of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved In Up To 85% Of Treatment-Naive Patients 11/10/2012

    Final Phase 2b data from Boehringer Ingelheim's interferon (IFN)-free Phase 2b SOUND-C2 study showed that up to 85 percent of genotype 1b (GT1b) hepatitis C (HCV) patients achieved sustained virologic response (SVR or viral cure) 12 and 24 weeks after the end of treatment with the investigational treatment regimen of faldaprevir (BI 201335) and BI 207127, in combination with ribavirin (RBV)